Le Lézard
Classified in: Science and technology
Subject: Survey

Torii Ranked as #1 SaaS Management Provider, According to New G2 Report

Torii, the SaaS Management pioneer, today announced it is the #1 rated SaaS Management Platform (SMP) vendor according to both of G2's newly-released SaaS Spend and Operations Management reports. Beating out other industry players, Torii received top customer satisfaction scores in the reports ? a testament to the company's product leadership and customer service.

IT teams trust Torii to better manage and optimize their singular SaaS ecosystem as the most innovative platform on the market. Earlier this month, Torii announced the latest release of its generative AI-powered platform, boasting several enhancements to improve how companies manage their SaaS stacks. Not only did Torii become the industry's only fully open SMP, but it also announced a suite of generative AI capabilities and one-of-a-kind enhancements to its SaaS Automation Center, including the industry's first Canvas Workflow Builder

"Torii's AI features have been a great help for us," said Raveh M. Kahaner, Head of Global Product at Hibob. "The platform is actually performing magic ? automatically uploading contracts, identifying applications, and answering SaaS questions in seconds. It saves us a lot of time."

Torii customers are aligned around this sentiment. According to the G2 reports, Torii boasts:

"Our job is to delight our customers, and for IT teams that means easing their workloads when it comes to managing IT spend, onboarding/offboarding, and so much more. With the release of our open platform and generative AI capabilities, we know we can do this at scale and have a real impact on IT team productivity," said Uri Haramati, CEO of Torii. "The G2 reports validate that we are doing right by our customers and our vision to create the one software to manage all software resonates with them. These ratings consistently show Torii is doing this better than any other SMP on the market."

G2 Grid Reports are based on real user reviews. G2 uses a proprietary algorithm to rank solutions from data aggregated from customers, online sources, and social networks. To access the G2 SaaS Operations and Spend Management Fall 2023 Grid reports, click here.

To learn more about how Torii is ushering in the next era of SaaS Management and helping IT pros meet more demands than ever before, visit the website.

About Torii
Torii empowers IT pros to solve modern SaaS challenges at their source?from Shadow IT to wasted spend and inefficient processes. Unlike other tools, IT pros rely on Torii to manage their entire SaaS ecosystem, discovering every SaaS app, optimizing SaaS investments, and automating SaaS tasks?all in one place. Our uniquely open platform allows IT to consolidate SaaS systems, tailor Torii to their company's evolving needs, and adopt best practices with ease. Now, IT can stay in the driver's seat while securing their company's sensitive data and empowering every stakeholder with the insights and actions they need.

Global customers such as Instacart, Sisense, Bumble, Hired, Athletic Greens, and Palo Alto Networks rely on Torii. The company is backed by Tiger Global Management, Wing Venture Capital, Global Founders Capital, Uncork Capital, Entree Capital, and Scopus Ventures. Learn more at www.toriihq.com and follow on Twitter @Torii_hq or LinkedIn.

These press releases may also interest you

at 12:35
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...

at 12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

at 12:05
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...

at 12:05
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...

at 11:35
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...

at 11:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab-kxwh) in previously untreated or minimally...

News published on and distributed by: